 Post (subscription) | 'Cancer drug price dropped' Post (subscription) The department's deputy director general for regulation Anban Pillay said the drug rituximab, dubbed MabThera by Roche, had previously been too expensive for the state to buy and distribute to patients. With the price halved, provinces with the ... |
